Does PCI Biotech Holding ASA's (OB:PCIB) CEO Pay Compare Well With Peers?

In 2008 Per Walday was appointed CEO of PCI Biotech Holding ASA (OB:PCIB). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we'll consider growth that the business demonstrates. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. The aim of all this is to consider the appropriateness of CEO pay levels.

Check out our latest analysis for PCI Biotech Holding

How Does Per Walday's Compensation Compare With Similar Sized Companies?

Our data indicates that PCI Biotech Holding ASA is worth øre959m, and total annual CEO compensation is øre2m. That's a notable increase of 15% on last year. We looked at a group of companies with market capitalizations under øre1.7b, and the median CEO compensation was øre3m.

So Per Walday receives a similar amount to the median CEO pay, amongst the companies we looked at. Although this fact alone doesn't tell us a great deal, it becomes more relevant when considered against the business performance.

The graphic below shows how CEO compensation at PCI Biotech Holding has changed from year to year.

Is PCI Biotech Holding ASA Growing?

Over the last three years PCI Biotech Holding ASA has grown its earnings per share (EPS) by an average of 17% per year. Its revenue is down -5.8% over last year.

This demonstrates that the company has been improving recently. A good result. While it would be good to see revenue growth, profits matter more in the end.

We don't have analyst forecasts, but you might want to assess this data-rich visualization of earnings, revenue and cash flow.

Has PCI Biotech Holding ASA Been A Good Investment?

Most shareholders would probably be pleased with PCI Biotech Holding ASA for providing a total return of 575% over three years. So they may not be at all concerned if the CEO is paid more than is normal for companies around the same size.

In Summary...

Per Walday is paid around what is normal the leaders of comparable size companies.

Few would be critical of the leadership, since returns have been juicy and earnings per share are moving in the right direction. So one could argue the CEO compensation is quite modest, if you consider company performance! CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling PCI Biotech Holding ASA (free visualization of insider trades).

Of course, the past can be informative so you might be interested in considering this analytical visualization showing the company history of earnings and revenue.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.

Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.